TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00219258
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01915732
Drug: Duac™Once Daily Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% clindamycin as clindamycin phosphate and 5% benzoyl peroxide
Study: NCT01915732
Drug: 1% clindamycin phosphate gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% clindamycin as clindamycin phosphate
Study: NCT00602030
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-matching entinostat tablets on Days 1 and 15 of a 28-day cycle.
Study: NCT02470832
Drug: RG1662
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03713892
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally administered
Study: NCT01360593
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine will be taken orally twice daily on days 1-14 every 3 weeks for 4 cycles (12 weeks) prior to stereotactic radiosurgery as follows:~Capecitabine 650 mg/m2 twice daily for days 1-14 every 3 weeks for up to 4 cycles.
Study: NCT01616732
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TU im
Study: NCT01616732
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo im
Study: NCT01730313
Drug: Pyridoxine
Normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01730313
Drug: Phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01730313
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00896831
Drug: L-ornithine-L-aspartate
Normalized name: ornithine, (L)-isomer
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-ornithine-L-aspartate: 5 g (1 sachet) three times per day for 60 days
Study: NCT00896831
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: 5 g (1 sachet) three times per day for 60 days
Study: NCT00041509
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo, oral, BID for 28 days
Study: NCT04132479
Drug: Clarithromycin 500mg
Normalized name: CLARITHROMYCIN 500MG TAB
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1000mg taken orally every 12 hours for 5 days
Study: NCT00363740
Drug: GW685698X Aqueous Nasal Spray
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00624208
Drug: saline and saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline and saline
Study: NCT04132479
Drug: Clarithromycin 500mg
Normalized name: CLARITHROMYCIN 500MG TAB
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1000mg taken orally every 12 hours for 14 days
Study: NCT01883167
Drug: RDEA3170 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: RDEA3170 10 mg once daily (qd)
Study: NCT01883167
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo qd
Study: NCT04587453
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo contains the same excipients in the same concentration only lacking tralokinumab.
Study: NCT00324792
Drug: intensive insulin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03136198
Drug: Intravenous Loop Diuretic
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV loop diuretic
Study: NCT03136198
Drug: Vasodilator
Normalized name: Vasodilator
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV, topical, or SL Vasodilator
Study: NCT00747175
Drug: AZD1656
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose titration to 3 (alt 4) increasing dose-steps with oral suspension, 8 days treatment
Study: NCT00747175
Drug: AZD1656
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose titration of oral suspension to a tolerable dose, 1 month treatment
Study: NCT02114697
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy includes rosuvastatin 20 mg administered orally, once a day, for the duration of the trial, which is 3 years. Participants may also receive a different type of statin as prescribed by their cardiologist based on clinical judgement.
Study: NCT02647983
Drug: Hyperpolarized Pyruvate (13C) Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperpolarized Pyruvate (13C) Injection is a MRI contrast agent.
Study: NCT00705419
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up for subjects who previously received placebo tablet administered once daily according to the parent protocol.
Study: NCT01072942
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo TID for 10 days
Study: NCT03907215
Drug: ACT541468
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg; film-coated tablet for oral use
Study: NCT03907215
Drug: ACT541468 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: film-coated tablet for oral use
Study: NCT03588338
Drug: Perfalgan
Normalized name: PERFALGAN
Approvals — FDA: no, EMA: no, PMDA: no
Description: For postoperative pain
Study: NCT01632709
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry needling
Study: NCT03335371
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 2: Participants will receive Placebo oral tablets for 12 weeks
Study: NCT01923077
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: usual care with Simvastatin
Study: NCT01923077
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: rosuvastatin 80 mg as loading dose at randomization followed by rosuvastatin 40 mg daily.
Study: NCT01969357
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets(n=4),once daily for 84 days
Study: NCT01969357
Drug: 50 mg SP2086
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets(n=1),50mg strength+tablets(n=3) 0 mg once daily for 84 days
Study: NCT00683137
Drug: valdecoxib
Normalized name: Valdecoxib
DrugBank: Valdecoxib (DB00580)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: valdecoxib 40 mg tablet by mouth followed by a valdecoxib 20 mg tablet by mouth after 1 to 12 hours of the initial dose on Day 1 then a valdecoxib 20 mg tablet by mouth once daily on Days 2 through 5
Study: NCT00683137
Drug: valdecoxib
Normalized name: Valdecoxib
DrugBank: Valdecoxib (DB00580)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: valdecoxib 40 mg tablet by mouth followed by a valdecoxib 20 mg tablet by mouth after 1 to 12 hours of the initial dose on Day 1 then a valdecoxib 20 mg tablet by mouth twice daily on Days 2 through 5
Study: NCT00683137
Drug: valdecoxib/placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: valdecoxib 40 mg tablet by mouth followed by a valdecoxib 20 mg tablet by mouth after 1 to 12 hours of the initial dose on Day 1 then placebo on Days 2 through 5
Study: NCT01551173
Drug: Fluvastatin sodium
Normalized name: Fluvastatin Sodium
DrugBank: Fluvastatin (DB01095)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluvastatin sodium Extended Release Tablets 80mg
Study: NCT03860688
Drug: TED + glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teduglutide, up to 0.05mg/kg, subcutaneous, single dose Glucose, 25g, oral, single dose
Study: NCT03569033
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet matching gefapixant will be administered orally.
Study: NCT00765557
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every subject will be given one bottle of the polyethylene glycol/placebo, divided into daily doses and depending on the patient's age, will be instructed to take 8.5 grams or 17 grams of the medication dispensed in daily dose vials to be mixed with water or juice. They will take the medication once a day for one month.
Study: NCT03295084
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose Escalation
Study: NCT00000371
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/day of placebo by mouth
Study: NCT03056248
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: On day 0, the day of the cardiac surgery placebo will be given once On day 1, one day after cardiac surgery placebo will be given once On day 2, two days after cardiac surgery placebo will be given once
Study: NCT01976208
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01426529
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A hormone that is normally present in your body, which regulates your blood pressure.
Study: NCT00617526
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01200472
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules identical to apremilast
Study: NCT04010799
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - Part I - SAD Placebo Part II - MAD
Study: NCT04500522
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 vaginal tablet of Placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
Study: NCT03108690
Drug: Continuous infusion of beta-lactam antibiotics .
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-lactam antibiotic will be administered as continous infusion.
Study: NCT06023797
Drug: Neoadjuvant immunochemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who received NAICT and were operated at the Department of Thoracic Surgery, Zhongshan Hospital Fudan University between 2017 and 2022.
Study: NCT00455871
Drug: reduced fluence photodynamic therapy with Visudyne
Approvals — FDA: no, EMA: no, PMDA: no
Description: reduced fluence photodynamic therapy with visudyne
Study: NCT00990405
Drug: Lansoprzole+Amoxicillin+Clarithromycin
Normalized name: lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole 30 mg bid, for 7 days Clarithromycin 500 mg bid, for 7 days Amoxicillin 1000 mg bid, for 7 days
Study: NCT01276782
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: It is FDA approved drug for thyroid disease
Study: NCT01170442
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo orally, daily for six months
Study: NCT01979965
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo therapy for three months
Study: NCT02226328
Drug: Midazolam and Fentanyl sedation
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00191009
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01575054
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-Blind Study Phase (12 weeks): On Day 1, normal saline (placebo) will be given by intramuscular injections into specified muscles of the lower limb, and optional injections may be administered into additional lower limb muscles.
Study: NCT02473809
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily
Study: NCT00469586
Drug: inhaled human insulin
Normalized name: insulin, regular, human Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treat-to-target dose titration scheme, pre-prandial, inhalation.
Study: NCT02929693
Drug: Yiqi-yangyin-jiedu decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yiqi-yangyin-jiedu decoction is a traditional chinese herbal medicine formula,and should be taken one package, twice a day, until progression or unacceptable toxicity develops.
Study: NCT02929693
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral granules, which the taste and smell are similar to YYJD, has no therapeutic effect, Oral granules, which the taste and smell are similar to experimental TCM granules, has no therapeutic effect, one package, twice a day, until progression or unacceptable toxicity develops.
Study: NCT04595136
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NS via nebulization
Study: NCT01372150
Drug: fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects randomized to the fluoxetine group receive 20 mg/day. Fluoxetine provided as oral capsules
Study: NCT01372150
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to the placebo group receive corresponding placebo tablets and/capsules
Study: NCT01617590
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX 7.5-15 mg, orally, once weekly for up to 48 weeks. Twelve weeks after the initial MTX induction, patients were randomized into two groups (MTX+CTX:LEF+MTX=2:1) if the DAS 28 were higher than 2.6, or continuing MTX use without dosing change. Then, the disease activity was assessed using DAS 28 every 12 weeks. The regimen should remain unchanged if the DAS 28 reached to less than 2.6, otherwise, a third (24 weeks) or fourth (36 weeks) DMARs should be added.~Intravenous CTX was administrated once
Study: NCT00284323
Drug: Adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004152
Drug: iodinated contrast dye
Normalized name: amaranth dye
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00648804
Drug: Zofran ODT® Tablets 8 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8mg, single dose fed
Study: NCT04585321
Drug: Diclofenac Sodium 140mg Medicated Plaster
Normalized name: diclofenac sodium Medicated Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1: two seven-day study periods, separated by at least 7 days of wash-out. In the first period, a single plaster of Test Drug or Reference Drug will be applied on the back (lumbar region) for seven consecutive days. In the second period, a single plaster of the Reference Drug or Test Drug will be applied on the back (lumbar region) daily for seven consecutive days.~Part 2: two seven-day study periods separated by at least 7 days of wash-out. In the first period, the Test Drug or Reference Drug plaster will be applied on the back (lumbar region) twice a day. In the second period, the Reference Drug or Test Drug plaster will be applied on the back (lumbar region) twice a day.
Study: NCT04585321
Drug: Flector® topical plaster containing 180 mg of diclofenac hydroxyethylpyrrolidine equivalent to 140 mg of sodium diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1: two seven-day study periods, separated by at least 7 days of wash-out. In the first period, a single plaster of Test Drug or Reference Drug will be applied on the back (lumbar region) for seven consecutive days. In the second period, a single plaster of the Reference Drug or Test Drug will be applied on the back (lumbar region) daily for seven consecutive days.~Part 2: two seven-day study periods separated by at least 7 days of wash-out. In the first period, the Test Drug or Reference Drug plaster will be applied on the back (lumbar region) twice a day. In the second period, the Reference Drug or Test Drug plaster will be applied on the back (lumbar region) twice a day.
Study: NCT01292161
Drug: Silymarin
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tab 210 mg, 630 mg, daily, six months.
Study: NCT00489203
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT00489203
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given after transplant
Study: NCT02377336
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match GS-6615 tablets administered orally
Study: NCT02702960
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pre-transplantation low dose cyclophosphamide given day -6 and -5 Post-transplantation high dose cyclophosphamide (PTCy; 50 mg/kg/day) will be administered on Days 3 and 4 with hydration
Study: NCT01224132
Drug: probiotic ® pur
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily, four types of probiotic bacteria ( Bifidobacterium bifidity, Lactobacillus acidophilus, Lactobacillus casei and Lactobacillus salivarium) 2 bags (two billion bacteria) (probiotic ® pur) for a total of 8 (eight) weeks
Study: NCT04488575
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsule
Study: NCT01101178
Drug: Reformulated OXY (oxycodone HCl)
Normalized name: Oxy Gard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reformulated OXY 80-mg tablet x 1 dose taken with food.
Study: NCT01101178
Drug: Original OxyContin® (OXY) (oxycodone HCl)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original OxyContin® (OXY) 80-mg tablet x 1 dose taken with food.
Study: NCT00858988
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice daily for 7 consecutive days
Study: NCT00944554
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given twice a day or five weeks.
Study: NCT00265733
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04152499
Drug: SKB264
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKB264 is an Antibody Drug Conjugate (ADC) targeting TROP2 expressing cancer cells.
Study: NCT00217451
Drug: Fosmidomycin-clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00474760
Drug: CP-751,871
Approvals — FDA: no, EMA: no, PMDA: no
Description: Currently dosing at 20 mg/kg, IV on day 1 of each 28 day cycle until progression or unacceptable toxicity
Study: NCT02846324
Drug: GBT440
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules which contain GBT440 drug substance in Swedish orange
Study: NCT02846324
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules
Study: NCT00928083
Drug: OZ439 400mg aqueous dispersion
Normalized name: ETHYLCELLULOSE AQUEOUS DISPERSION TYPE A
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01937299
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive ingredients used as a placebo comparator
Study: NCT00928083
Drug: OZ439 800mg aqueous dispersion
Normalized name: ETHYLCELLULOSE AQUEOUS DISPERSION TYPE A
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00091858
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Q4W
Study: NCT03167918
Drug: Calcium Dobesilate
Normalized name: CALCIUM DOBESILATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: gave each patient 0.5 g bid，
Study: NCT03167918
Drug: Xuefuzhuyu Decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: gave each patient100 ml bid，po
Study: NCT03167918
Drug: Xuefuzhuyu Decoction & Calcium dobesilate
Approvals — FDA: no, EMA: no, PMDA: no
Description: gave each patient Calcium dobesilate 0.5 g bid，po and Xuefuzhuyu Decoction 100 ml bid，po
Study: NCT00928083
Drug: OZ439 1600mg aqueous dispersion
Normalized name: ETHYLCELLULOSE AQUEOUS DISPERSION TYPE A
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00928083
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00928083
Drug: OZ439 200mg aqueous dispersion
Normalized name: ETHYLCELLULOSE AQUEOUS DISPERSION TYPE A
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00952783
Drug: Lesion count
Normalized name: scabies lesion lysate (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lesion count in area treated by study drug in a prior study over a 12 month period No drug will be applied during this long-term follow up study. Drug was applied during the primary study.
Study: NCT02532764
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline
Study: NCT00003399
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00926406
Drug: lead chelation therapy
Normalized name: lead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with lead poisoning (BLL\> 20μg/dl) are randomly assigned to a control or chelation group, on the 1:1 proportion. During the 3 months, 50 chelation group patients receive 2-hour weekly intravenous infusions of one vial (1 g) of calcium di-sodium EDTA mixed with 200 ml of normal saline until BLB is BLL \< 5 μg/dl. Fifty control patients receive weekly 2-hour infusions of one vial (20 ml) of 50% glucose mixed with 200 ml of normal saline over a period of 12 weeks9.
Study: NCT02584140
Drug: Daily Oral PrEP
Normalized name: Daily Hist Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will be offered daily oral emtricitabine/tenofovir disoproxil fumarate for Pre-exposure Prophylaxis.
Study: NCT01695109
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl, 0.2 ml
Study: NCT02402166
Drug: SPD489
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will begin with 5mg of SPD489 daily and will be titrated until optimal dose is reached (5, 10, 15, 20, and 30mg)
Study: NCT02635243
Drug: SAR438544
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:solution~Route of administration: subcutaneous
Study: NCT04032548
Drug: Placebo mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: After using mouthwash for 21 days, they are instructed to refrain from mouthwash for 14 days (wash out period).
Study: NCT00487227
Drug: caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00487227
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03331042
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical in appearance to SM-1, D+Z and D+L and has the same excipients, but no diphenhydramine, zolpidem, lorazepam or delayed-release coating materials.
Study: NCT00942851
Drug: Acetyl-Hexapeptide Topical Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: AH-8 containing topical treatment
Study: NCT00942851
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical treatment NOT containing AH-8
Study: NCT00720759
Drug: D-cycloserine + distributed treatment
Normalized name: D-(+)-cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive CIMT 2 hours/day, 3 days a week, for 10 weeks, in conjunction with d-cycloserine 50 mg PO administered before each treatment session